Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Development of New Software Capabilities for Use With Cardiovascular Magnetic Resonance Imaging (CVMRI)

This study has been terminated.
(Principal Investigator is deceased)
Information provided by (Responsible Party):
John M. Brock, University of California, Davis Identifier:
First received: January 3, 2008
Last updated: November 30, 2015
Last verified: November 2015
This Protocol is intended to facilitate development and testing of new cardiovascular MRI software capabilities by UC Davis Research Faculty, as well as to facilitate the evaluation of new software capabilities provided by GE and Siemens.

Abnormalities, Cardiovascular

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Prospective
Official Title: Development of New Software Capabilities for Use With Cardiovascular Magnetic Resonance Imaging

Resource links provided by NLM:

Further study details as provided by University of California, Davis:

Primary Outcome Measures:
  • Extend or generalize certain capabilities, such as new data acquisition pulse sequences, new image processing and analysis software for structural and functional analysis of the MR images [ Time Frame: Post-scanning ]

Secondary Outcome Measures:
  • Improve image quality by various techniques (e.g. reducing the effects of motion) [ Time Frame: Post-scanning ]

Enrollment: 42
Study Start Date: May 1999
Study Completion Date: July 2014
Primary Completion Date: July 2014 (Final data collection date for primary outcome measure)
Detailed Description:
This protocol will permit normal subjects, as well as patients with suspected or proven medical conditions, to undergo MRI studies using the new software capabilities. This Protocol is not restricted to imaging of a particular organ system or disease. The Protocol does not involve injection of any contrast agent, or other minimally-invasive or invasive procedure. It is intended only for those cases for which the only requirement of the subject is to relax and lie still while imaging is being performed.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
Noraml volunteers and patients with known or suspected cardiovascular disease

Inclusion Criteria:

  • 18 years of age or older
  • Ability to give informed, written consent
  • Not Pregnant or breastfeeding

Exclusion Criteria:

  • Electrically, magnetically, or mechanically activated implants (for example, cardiac-pacemakers)
  • Ferromagnetic implant, such as an aneurysm clip, surgical clip, or prosthesis
  • History of uncontrolled claustrophobia
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00593541

Sponsors and Collaborators
John M. Brock
Principal Investigator: Michael H Buonocore, MD, PhD University of California, Davis
  More Information

Responsible Party: John M. Brock, Principal Investigator, University of California, Davis Identifier: NCT00593541     History of Changes
Other Study ID Numbers: 200210689
Study First Received: January 3, 2008
Last Updated: November 30, 2015

Keywords provided by University of California, Davis:

Additional relevant MeSH terms:
Cardiovascular Abnormalities
Cardiovascular Diseases
Congenital Abnormalities processed this record on May 23, 2017